Published in Lakartidningen on July 27, 2005
Urinary bladder cancer treated with radical cystectomy: perioperative parameters and early complications prospectively registered in a national population-based database. Scand J Urol (2014) 2.07
Guidelines on bladder cancer. Eur Urol (2002) 1.97
Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol (2007) 1.70
Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res (2007) 1.68
Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int (2005) 1.58
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol (2011) 1.51
Defecation disturbances after cystectomy for urinary bladder cancer. BJU Int (2010) 1.46
Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. J Urol (2003) 1.33
Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol (2004) 1.28
Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol (2010) 1.24
Zinc-based fixative improves preservation of genomic DNA and proteins in histoprocessing of human tissues. Lab Invest (2003) 1.23
Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2. Scand J Urol Nephrol (2002) 1.14
Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology (2006) 1.14
Impact of thawing on RNA integrity and gene expression analysis in fresh frozen tissue. Diagn Mol Pathol (2009) 1.13
A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol (2004) 1.13
Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics (2011) 1.09
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol (2012) 1.04
Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol (2012) 1.03
Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int J Cancer (2010) 0.99
Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol (2013) 0.96
Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. Urology (2005) 0.92
Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol (2006) 0.90
Hygiene and urinary tract infections after cystectomy in 452 Swedish survivors of bladder cancer. BJU Int (2009) 0.89
Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med (2007) 0.88
[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res (2007) 0.87
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer. Acta Oncol (2004) 0.87
Patient-assessed outcomes in Swedish and Egyptian men undergoing radical cystectomy and orthotopic bladder substitution--a prospective comparative study. Urology (2007) 0.87
HER-2--a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol (2002) 0.86
Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. Int J Cancer (2006) 0.86
Results of second-look resection after primary resection of T1 tumour of the urinary bladder. Scand J Urol Nephrol (2005) 0.84
Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: a Swedish population-based survey. Scand J Urol Nephrol (2011) 0.83
Use of bacillus Calmette-Guérin in stage T1 bladder cancer: Long-term observation of a population-based cohort. Scand J Urol (2014) 0.83
A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. Scand J Urol Nephrol (2009) 0.82
Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scand J Urol (2015) 0.82
High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals. Prostate (2009) 0.82
Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology (2005) 0.82
Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts. BMC Urol (2014) 0.82
Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion. Nucl Med Biol (2004) 0.82
A novel strategy based on histological protein profiling in-silico for identifying potential biomarkers in urinary bladder cancer. BJU Int (2009) 0.81
Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol (2006) 0.80
Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. Nucl Med Biol (2005) 0.79
Tumour expression of bladder cancer-associated urinary proteins. BJU Int (2013) 0.79
Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU Int (2007) 0.79
Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden. Scand J Urol (2013) 0.79
Urinary diversion after cystectomy for bladder cancer: a population-based study in Sweden. Scand J Urol Nephrol (2010) 0.78
EGF-receptor targeted liposomes with boronated acridine: growth inhibition of cultured glioma cells after neutron irradiation. Int J Radiat Biol (2005) 0.77
The prognostic role of the STK15 T91A polymorphism and of STK15 mRNA expression in patients with urothelial cell carcinoma. Anticancer Res (2007) 0.77
An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay. Int J Oncol (2005) 0.76
Re: extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol (2004) 0.75
The star chart to Ta bladder cancer: an unsophisticated analysis of two-dimensional gel electrophoresis proteome maps. Scand J Urol Nephrol (2010) 0.75
Prognostic markers for urothelial cancer: obstacles and opportunities. Urol Oncol (2012) 0.75
Scandinavian Journal of Urology. Scand J Urol (2013) 0.75
In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab. Cancer Biother Radiopharm (2007) 0.75
[What is good quality prostatic cancer care?]. Lakartidningen (2007) 0.75
[Can medical students learn urology at county hospitals? Report from an IT-based developmental project in medical education]. Lakartidningen (2008) 0.75
[Fast measures in macro hematuria are both necessary and possible]. Lakartidningen (2012) 0.75